Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-09-18

Clinical Trial Update: Solifenacin Succinate Versus Tolterodine 4mg Once Daily [Phase 3]

View source ↗

Summary

A Phase 3 study comparing solifenacin succinate to tolterodine 4 mg once daily in adults with overactive bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Detrol (tolterodine)
  • Vesicare (solifenacin succinate)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: COMPLETED